Europe Human Albumin Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The Europe Human Albumin Market size is expected to reach US$ 1,544.7 Million by 2031 from US$ 1,057.5 Million in 2024. The market is estimated to record a CAGR of 5.7% from 2025 to 2031.

Executive Summary and Europe Human Albumin Market Analysis:

The rising prevalence of advanced liver disease in the region-such as chronic viral hepatitis leading to cirrhosis and hepatocellular carcinoma-is increasing demand for albumin therapies. In 2022, the age-standardized incidence of liver cancer in the EU-27 was 12.8 cases per 100,000 (19.5 for males) and mortality 11.1 deaths per 100,000 (17.2 for males) in that year. The European Centre for Disease Prevention and Control (ECDC) estimated that 3.6 million people in the EU/EEA live with chronic hepatitis B and approximately 2.4 million with chronic hepatitis C-both major precursors to hypo-albuminemia and cirrhosis. In Denmark, public hospitals in 2022 administered 14,888 L of albumin solutions-approximately 1 % of the total 1,543,199 L of issued resuscitative fluids-showing the scale of therapeutic adoption in acute settings. In 2022, Grifols opened a new albumin purification and filling facility in Ireland, aiming to triple annual capacity and respond to rising demand in Europe. Germany's regulatory body lists numerous valid marketing authorizations for human albumin products across strength formats. The well-developed plasma-collection infrastructure in Western Europe, combined with centuries-old use of albumin for hypoalbuminemia, burns, and volume-resuscitation (noted in EU regulatory summary guidelines), has provided a stable structural base for supply and adoption

Europe Human Albumin Market: Strategic Insights

Europe Human Albumin Market Segmentation Analysis:

• By Application, the Europe Human Albumin Market is segmented into Therapeutic Applications, Drug Delivery, Disease Diagnostics, Research, and Others. The Therapeutic Applications segment dominated the market in 2024.
• By Therapeutic Application, the Europe Human Albumin Market is segmented into Liver and Kidney Diseases, Surgery, Hypovolemia and Hypoalbuminemia, and Others. The Hypovolemia and Hypoalbuminemia segment dominated the market in 2024.
• By End User, the Europe Human Albumin Market is segmented into Hospitals and Clinics, Pharmaceutical and Biotechnological Companies, Research Institutes, Diagnostic Laboratories, Homecare Settings, and Others. The Hospitals and Clinics segment dominated the market in 2024.

Europe Human Albumin Market Players Density: Understanding Its Impact on Business Dynamics

The Europe Human Albumin Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Europe Human Albumin Market Outlook

Globally, chronic kidney disease (CKD) continues to pose a significant public health burden. In 2023, an estimated 788 million adults aged 20 years and older were living with CKD, compared with 378 million in 1990, highlighting the substantial growth in disease prevalence over the past three decades. The global age-standardized prevalence of CKD reached 14.2% in 2023. CKD patients, especially those on dialysis or with nephrotic-range proteinuria, may suffer severe hypoalbuminemia and fluid imbalances, increasing the clinical need for albumin infusions. As dialysis techniques become more prevalent and kidney failure care expands globally, albumin may be used in hemodynamic support, plasma volume expansion, or nutritional supplementation in hypoalbuminemia states. In parallel, albumin‐product manufacturers are adapting to meet this need: for example, developing high-purity, large-volume albumin solutions or combination therapies in nephrology settings. The combination of rising CKD prevalence, the large cost burden documented by government data, and the therapeutic use of albumin in kidney failure drives the growth of the human albumin market.

Europe Human Albumin Market Country Insights

By country, the Europe Human Albumin Market is segmented into Germany, the United Kingdom, France, Spain, Italy, and the Rest of Europe. Germany held the largest share in 2024.

The Germany Human Albumin Market is growing due to escalating demand from surging liver failure cases, critical surgeries, and burn treatments. Liver transplants rose from 746 in 2022 to 868 in 2023 and 890 in 2024, per Deutsche Stiftung Organtransplantation (DSO) annual reports. The transplantable waiting list hit 904 patients by end-2024 (DSO). Hospital cases for burns and corrosions reached 33,653 in 2024 (Destatis DRG-Statistics). Total surgical procedures topped 16.3 million in 2024, amid recovering volumes with 17.2 million inpatient treatments in 2023, up 2.4% from 2022 (Destatis). Paul-Ehrlich-Institut (PEI) maintains supply via approvals for products such as HUMAN ALBUMIN 250 g/l Baxalta and Human-Albumin 20% Behring, critical for hypoalbuminemia in ICUs and post-op care.

Europe Human Albumin Market Company Profiles

Some of the key players operating in the market include CSL Ltd, Biotest AG., Octapharma AG, Takeda Pharmaceutical Co Ltd, Merck KGaA, Grifols SA, Taibang Bio Group Co. Ltd., HiMedia Laboratories Pvt Ltd, Thermo Fisher Scientific Inc., and InVitria.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Europe Human Albumin Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise